mRNA splicing inhibitor; decreases splicing capacity up to 75% in vitro
. Directly targets splicesome-associated 130 (SAP130), inhibits splicing factor 3B subunit (SF3B1) and impairs U2 small nuclear ribonucleoprotein (U2 snRNP) interaction with pre-mRNA. Arrests cell cycle in G1
phases. Displays antitumor activity against gastric cancer cells (IC50
values are 1.6-4.9 nM). Cell permeable and active in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Splicing controls the ubiquitin response during DNA double-strand break repair.
Pederiva C, Bohm S, Julner A, Farnebo M.
Cell Death Differ.
Therapeutic targeting of splicing in cancer.
Lee et al.
Nature Medicine, 2016;22:976
High antitumor activity of pladienolide B and its derivative in gastric cancer.
Sato et al.
Cancer Sci., 2014;105:110
The citations listed below are publications that use Tocris products. Selected citations for Pladienolide B include:
4 Citations: Showing 1 - 4
Filter your results: